We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Oculis

News List

Oculis Strengthens Leading Ophthalmology Pipeline by In-Licensing Neuroprotective Drug Candidate for Glaucoma from Accure Therapeutics PharmaSources.com
March 08, 2022
Oculis S.A., (Oculis) a global ophthalmology company developing life-changing treatments to save sight and improve eye care with breakthrough innovations, and Accure Therapeutics, a private translational neuroscience R&D company...
AGC Biologics and Oculis Enter Manufacturing Deal contractpharma
May 08, 2021
AGC Biologics, a global biopharmaceutical contract development and manufacturing organization (CDMO), has entered a partnership with Oculis to manufacture OCS-02, a Phase II investigational drug targeting both Dry Eye Disease and Anterior Uveitis ...
Oculis Reports Positive Data from OCS-01 Trial for Cataract Surgery Pain, Inflammation americanpharmaceuticalreview
May 28, 2020
Oculis has reported positive results from its Phase 2 SKYGGN study of OCS-01.
Swiss biotech Oculis raises cash, nabs Novartis eye drug in extended series B fiercebiotech
January 07, 2019
Hoping to push on with its work on next-gen eye treatments, Oculis has raised an extra CHF 15 million ($15.2 million) as it looks to fellow native Swiss biopharma Novartis for its next project....